THE WHO on Wednesday (3) said it granted emergency use listing (EUL) to Bharat Biotech's Covid-19 vaccine Covaxin.
This comes after the Technical Advisory Group (TAG), an independent advisory committee of the WHO, recommended EUL status for Covaxin.
"WHO has granted emergency use listing (EUL) to #COVAXIN (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19," the global health body said in a tweet.
Dr Poonam Khetarpal Singh, regional director of WHO south East Asia, in a tweet, said, "Congratulations India for Emergency Use Listing of its indigenously produced COVID-19 vaccine Covaxin."
On October 26, the TAG had sought "additional clarifications" from the company for Covaxin to conduct a final "risk-benefit assessment" for emergency use listing of the vaccine.
The TAG-EUL is an independent advisory group that provides recommendations to WHO on whether a Covid-19 vaccine can be listed for emergency use under the EUL procedure.
Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2 per cent protection against the new Delta variant.
In June, the company said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.
Bharat Biotech's Covaxin and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India.
(PTI)
Nirmala Sitharaman speaks at the India-UK Investor Roundtable in London last Wednesday (9). On the panel were India’s department of economic affairs secretary Ajay Seth and Kotak Mahindra Bank founder Uday Kotak
Sitharaman with Sir Keir Starmer and Rachel Reeves
Sitharaman with Jonathan Reynolds 
Sitharaman with Reynolds, Alastair King, India’s high commissioner Vikram Doraiswami and other delegates
